• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The ACCOMPLISH trial: ACE inhibitors and calcium channel blockers for hypertension [Classics Series]

byAndrew Cheung, MD MBA
November 9, 2014
in General Medicine Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Benazepril plus amlodipine offers the same effect at reducing blood pressure in hypertensive patients as benazepril plus hydrochlorothiazide.

2. Benazepril plus amlodipine was more effective than benazepril plus hydrochlorothiazide at reducing cardiovascular events in hypertensive patients at risk for such events.

Original Date of Publication: December 2008

Study Rundown: The Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial sought to compare a thiazide with a calcium channel blocker (CCB) as combination therapy with an angiotensin-converting-enzyme (ACE) inhibitor in reducing cardiovascular events in patients with hypertension. Patients with hypertension and cardiovascular risk factors were randomized to treatment with benazepril plus amlodipine or benazepril plus hydrochlorothiazide (HCTZ). In summary, patients in the benazepril-amlodipine group experienced significantly lower rates of the primary outcome compared to those in the benazepril-HCTZ group (HR 0.80; 95%CI 0.72-0.90). This was due to a significant reduction in the rates of fatal/nonfatal myocardial infarction, while there was no significant difference in the rate of death from cardiovascular causes. This study demonstrated that adding a CCB to an ACE inhibitor reduces the risk of myocardial infarction when compared to adding a thiazide diuretic for blood pressure control in hypertensive patients. It is important to note that Novartis was significantly involved in the execution of the study – from coordination to data analysis. Moreover, the study was stopped early by the executive committee, as preliminary results met premature termination conditions.

Click to read study in NEJM

In-Depth [randomized, controlled trial]: A total of 11,506 patients from 548 centres in the United States, Sweden, Norway, Denmark, and Finland were randomized to receive either 1) benazepril plus amlodipine or 2) benazepril plus HCTZ. Patients were started on therapy with either benazepril 20 mg and amlodipine 5 mg daily or benazepril 20 mg and HCTZ 12.5 mg daily. Patients were eligible if they had hypertension, a history of coronary events/myocardial infarction/revascularization/stroke, impaired renal function, peripheral artery disease, left ventricular hypertrophy, or diabetes mellitus. Medication doses were adjusted in the first 3 months to maintain a blood pressure ≤140/90, or ≤130/80 in patients with diabetes and kidney disease. Patients were followed every 6 months, and dose adjustments were performed during these visits. The primary endpoint was a composite of cardiovascular events or death from cardiovascular causes. Of note, the study was funded by Novartis, which was also involved in overseeing coordination, data gathering, and data analysis.

RELATED REPORTS

Hypotension- and hypertension-avoidance strategies may yield similar neurocognitive outcomes following noncardiac surgery

Maternal hypertension associated with adverse neurodevelopment outcomes in preterm infants

#VisualAbstract: Sotatercept Improves Outcomes in Patients with Pulmonary Arterial Hypertension at High Risk for Death

Mean blood pressures were 131.6/73.3 mmHg in the benazepril-amlodipine group and 132.5/74.4 mmHg in the benazepril-hydrochlorothiazide group. The mean difference in blood pressure was 0.9 mm Hg systolic and 1.1 mm Hg diastolic (p<0.001). The trial was terminated early by the executive committee. Patients in the benazepril-amlodipine group experienced a significantly lower rate of the primary endpoint as compared with patients in the benazepril-HCTZ group (HR 0.80; 95%CI 0.72-0.90), with an absolute risk reduction of 2.2%. This difference was due to a significant lower rates of fatal and nonfatal myocardial infarction in the benazepril-amlodipine group (HR 0.78; 95%CI 0.62-0.99), while there was no significant difference between the two groups in death from cardiovascular causes.

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: ACCOMPLISHACE inhibitorshypertension
Previous Post

Decreased trainee autonomy suggested with in-hospital intensivist coverage

Next Post

PG-13/R movies similar in violence and risk behavior volume

RelatedReports

Chronic Disease

Hypotension- and hypertension-avoidance strategies may yield similar neurocognitive outcomes following noncardiac surgery

June 4, 2025
Prevalence of hypertension among adolescents varies by race and BMI
Chronic Disease

Maternal hypertension associated with adverse neurodevelopment outcomes in preterm infants

May 10, 2025
#VisualAbstract: Sotatercept Improves Outcomes in Patients with Pulmonary Arterial Hypertension at High Risk for Death
StudyGraphics

#VisualAbstract: Sotatercept Improves Outcomes in Patients with Pulmonary Arterial Hypertension at High Risk for Death

April 17, 2025
Prevalence of hypertension among adolescents varies by race and BMI
Cardiology

App-based physical activity intervention may have a limited role among women with prior hypertensive pregnancy disorder

April 11, 2025
Next Post
PG-13/R movies similar in violence and risk behavior volume

PG-13/R movies similar in violence and risk behavior volume

New genetic link in pulmonary arterial hypertension holds therapeutic promise

New gene associated with essential thrombocytopenia and primary myelofibrosis

Primary care and specialists have comparable outcomes in treating Sleep Apnea

CPAP use linked to improvements in resistant hypertension in OSA (HIPARCO Trial)

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Intravenous hydrocortisone may reduce risk of kidney failure in patients with sepsis
  • Sotatercept reduces adverse event risk in high-risk pulmonary arterial hypertension
  • Oral semaglutide reduces cardiovascular event rates in high-risk patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.